136 related articles for article (PubMed ID: 8514459)
1. Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy.
Lala PK; Parhar RS
Int J Cancer; 1993 Jun; 54(4):677-84. PubMed ID: 8514459
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2.
Khoo NK; Chan FP; Saarloos MN; Lala PK
Clin Exp Metastasis; 1992 Jul; 10(4):239-52. PubMed ID: 1617832
[TBL] [Abstract][Full Text] [Related]
3. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ.
Lala PK; Elkashab M; Kerbel RS; Parhar RS
Int Immunol; 1990; 2(12):1149-58. PubMed ID: 2090199
[TBL] [Abstract][Full Text] [Related]
4. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
5. Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.
Parhar RS; Lala PK
J Exp Med; 1987 Jan; 165(1):14-28. PubMed ID: 3491867
[TBL] [Abstract][Full Text] [Related]
6. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice.
Orucevic A; Lala PK
Br J Cancer; 1996 Jan; 73(2):189-96. PubMed ID: 8546905
[TBL] [Abstract][Full Text] [Related]
7. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.
Parhar RS; Lala PK
J Leukoc Biol; 1988 Dec; 44(6):474-84. PubMed ID: 2973508
[TBL] [Abstract][Full Text] [Related]
9. Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis.
Saarloos MN; Khoo NK; Lala PK
Clin Exp Metastasis; 1993 May; 11(3):275-83. PubMed ID: 8097142
[TBL] [Abstract][Full Text] [Related]
10. Cure of murine Ehrlich ascites tumors with chronic oral indomethacin therapy combined with intraperitoneal administration of LAK cells and IL-2.
Lala PK; Parhar RS; Singh P; Lala PK
Cancer Lett; 1990 May; 51(1):27-35. PubMed ID: 2337895
[TBL] [Abstract][Full Text] [Related]
11. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
12. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis.
Lala PK; Parhar RS; Singh P
Cell Immunol; 1986 Apr; 99(1):108-18. PubMed ID: 2944621
[TBL] [Abstract][Full Text] [Related]
13. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
Mulé JJ; Yang JC; Afreniere RL; Shu SY; Rosenberg SA
J Immunol; 1987 Jul; 139(1):285-94. PubMed ID: 3108401
[TBL] [Abstract][Full Text] [Related]
14. Indomethacin-enhanced immunotherapy of pulmonary metastases using IL-2 and IFN-alpha.
Kim B; Warnaka P
Surgery; 1989 Aug; 106(2):248-55; discussion 255-6. PubMed ID: 2788316
[TBL] [Abstract][Full Text] [Related]
15. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice.
Lala PK; Al-Mutter N; Orucevic A
Int J Cancer; 1997 Nov; 73(3):371-80. PubMed ID: 9359485
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination. effects on tumour growth, capillary leakage and nitric oxide (NO) production.
Timoshenko AV; Lan Y; Gabius HJ; Lala PK
Eur J Cancer; 2001 Oct; 37(15):1910-20. PubMed ID: 11576848
[TBL] [Abstract][Full Text] [Related]
17. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon.
Dinney CP; Utsugi T; Fidler IJ; von Eschenbach AC; Killion JJ
Cancer Res; 1992 Mar; 52(5):1155-61. PubMed ID: 1531322
[TBL] [Abstract][Full Text] [Related]
19. Specific chemoimmunotherapy in tumor-bearing mice with extracted antigen, cyclophosphamide, and intrasplenic administration of interleukin-2.
Kahan BD; Nomi S; Pellis NR
Cancer; 1986 Feb; 57(3):477-83. PubMed ID: 3484658
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
